Stereotactic Body Radiotherapy Using CyberKnife for Metastatic Liver Tumors: A Single-center Retrospective Study.

IF 1.6 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2025-03-01 DOI:10.21873/anticanres.17500

Yasuhiro Ryuno, Takanori Abe, Keita Tsukahara, Jun Watanabe, Misaki Iino, Satoshi Saito, Tomomi Aoshika, Tomohiro Ohta, Mitsunobu Igari, Ryuta Hirai, Y U Kumazaki, Shin-Ei Noda, Shingo Kato

{"title":"Stereotactic Body Radiotherapy Using CyberKnife for Metastatic Liver Tumors: A Single-center Retrospective Study.","authors":"Yasuhiro Ryuno, Takanori Abe, Keita Tsukahara, Jun Watanabe, Misaki Iino, Satoshi Saito, Tomomi Aoshika, Tomohiro Ohta, Mitsunobu Igari, Ryuta Hirai, Y U Kumazaki, Shin-Ei Noda, Shingo Kato","doi":"10.21873/anticanres.17500","DOIUrl":null,"url":null,"abstract":"Background/aim: Liver metastases are a major cause of cancer-related mortality and present significant therapeutic challenges. Chemotherapy is preferred for multiple metastases, while surgery or stereotactic body radiotherapy (SBRT) is used for solitary or few metastases, particularly in oligometastatic cases. This study aimed to evaluate the safety and efficacy of CyberKnife SBRT (CK-SBRT) for liver oligometastases.Patients and methods: This retrospective study analyzed patients with one to three liver metastases treated with CK-SBRT. The prescribed dose was typically 60 Gy in four fractions to 95% of the target volume, with reductions allowed if organ-at-risk (OAR) constraints could not be met. The local control (LC) and overall survival (OS) rates were estimated using the Kaplan-Meier method, and liver dose-volume parameters were assessed.Results: A total of 39 liver lesions in 27 patients were treated. At a median follow-up of 17 months, the 1-year LC and OS rates were 90% and 80%, respectively. In patients receiving 60 Gy in four fractions, these rates were 95% and 86%. No severe liver toxicity or radiation-induced liver disease occurred. Most patients met liver dose constraints, with low liver V15 and mean liver dose values.Conclusion: CK-SBRT provides effective tumor control with minimal toxicity for liver oligometastases. Careful dose planning and adherence to OAR constraints are essential to minimize toxicity risks.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"1127-1136"},"PeriodicalIF":1.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17500","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Liver metastases are a major cause of cancer-related mortality and present significant therapeutic challenges. Chemotherapy is preferred for multiple metastases, while surgery or stereotactic body radiotherapy (SBRT) is used for solitary or few metastases, particularly in oligometastatic cases. This study aimed to evaluate the safety and efficacy of CyberKnife SBRT (CK-SBRT) for liver oligometastases.

Patients and methods: This retrospective study analyzed patients with one to three liver metastases treated with CK-SBRT. The prescribed dose was typically 60 Gy in four fractions to 95% of the target volume, with reductions allowed if organ-at-risk (OAR) constraints could not be met. The local control (LC) and overall survival (OS) rates were estimated using the Kaplan-Meier method, and liver dose-volume parameters were assessed.

Results: A total of 39 liver lesions in 27 patients were treated. At a median follow-up of 17 months, the 1-year LC and OS rates were 90% and 80%, respectively. In patients receiving 60 Gy in four fractions, these rates were 95% and 86%. No severe liver toxicity or radiation-induced liver disease occurred. Most patients met liver dose constraints, with low liver V15 and mean liver dose values.

Conclusion: CK-SBRT provides effective tumor control with minimal toxicity for liver oligometastases. Careful dose planning and adherence to OAR constraints are essential to minimize toxicity risks.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.